Your competent? doctor has created protocols on the use of IGF-1 years ago, right?
Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING?
‘Designer Drug’ Shows Early Neuroprotective Signal in Acute Ischemic Stroke
BARCELONA, Spain — An experimental drug that takes a novel approach to protecting injured brain cells has shown promising results in an early Phase 2 trial of patients with acute ischemic stroke (AIS).
Known as Scp776, the drug is based on insulin-like growth factor 1 (IGF-1), which plays a key role in brain health by protecting neurons from excitotoxicity, hypoglycemic damage, oxidative stress, inflammation, and apoptosis.
In the Phase 2a ARPEGGIO study, the drug showed preliminary signs of neurologic improvement compared with placebo in patients with large-vessel occlusion (LVO) stroke treated within the late time window (up to 24 hours after symptom onset).
Those treated with Scp776 showed a trend toward better National Institutes of Health Stroke Scale (NIHSS) scores, which measure stroke severity, at 7 days, and improved modified Rankin Scale (mRS) scores, which assess functional outcomes, at 90 days.
The drug also appeared to be safe and well tolerated with no serious adverse events compared with placebo.“This is a unique and innovative drug, and these early results are very exciting” lead investigator of the ARPEGGIO trial, study investigator, Eva Mistry, MD, associate professor of neurology at the University of Cincinnati, Cincinnati, told Medscape Medical News.
No comments:
Post a Comment